<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37811052</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-0801</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of medicine and surgery (2012)</Title><ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation></Journal><ArticleTitle>A cerebral lymphoma mimicking a meningioma: case report.</ArticleTitle><Pagination><StartPage>5100</StartPage><EndPage>5104</EndPage><MedlinePgn>5100-5104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MS9.0000000000001126</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Cerebral lymphoma is a rare and aggressive brain tumor. It accounts for 1% of all non-Hodgkin's lymphomas (NHL) and 2% of all brain tumors. Untreated brain lymphoma has a very poor prognosis, with an overall life expectancy of around 1.5 months.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="UNASSIGNED">The authors report the case of a 35-year-old patient, with no previous pathological history, who presented for 3 weeks with deafness and recently aggravated otalgia. In MRI, brain imaging revealed a formation initially suggestive of an aggressive meningioma, and the histological study of the operative specimen was in favor of a diffuse large-cell non-germ-center B NHL.</AbstractText><AbstractText Label="CLINICAL DISCUSSION" NlmCategory="UNASSIGNED">Primary central nervous system lymphoma is an extra-nodal NHL localized to the brain, meninges, spinal cord, and eyes. In 90% of cases, these are diffuse large B-cell lymphomas, the other types being poorly characterized low-grade lymphomas, T-cell lymphomas, and Burkitt's lymphomas. MRI with gadolinium contrast is the gold standard for diagnosis which enhancement is homogeneous and well-limited, frequently associated with perilesional vascular edema. In T2-weighted sequences, there is a weak signal with restricted diffusion on diffusion-weighted imaging. The management of brain lymphoma is currently based on chemotherapy with high-dose methotrexate combined with the other agents, mainly rituximab.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Cerebral lymphoma remains a non-negligible entity of central nervous system tumors, which can be confused with several other tumors, mainly glial and meningioma.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joudar</LastName><ForeName>Imane</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Pharmacy, Mohammed First University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Mohammed VI University Hospital, Mohammed First University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasri</LastName><ForeName>Siham</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Pharmacy, Mohammed First University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Mohammed VI University Hospital, Mohammed First University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Pharmacy, Mohammed First University, LAMCESM, Oujda, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aichouni</LastName><ForeName>Narjisse</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Pharmacy, Mohammed First University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Mohammed VI University Hospital, Mohammed First University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamaoui</LastName><ForeName>Imane</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Pharmacy, Mohammed First University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Mohammed VI University Hospital, Mohammed First University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skiker</LastName><ForeName>Imane</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Pharmacy, Mohammed First University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Mohammed VI University Hospital, Mohammed First University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Pharmacy, Mohammed First University, LAMCESM, Oujda, Morocco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med Surg (Lond)</MedlineTA><NlmUniqueID>101616869</NlmUniqueID><ISSNLinking>2049-0801</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MRI brain imaging</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">extra-nodal lymphoma</Keyword><Keyword MajorTopicYN="N">neurotoxicity</Keyword><Keyword MajorTopicYN="N">primary CNS lymphoma</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37811052</ArticleId><ArticleId IdType="pmc">PMC10553179</ArticleId><ArticleId IdType="doi">10.1097/MS9.0000000000001126</ArticleId><ArticleId IdType="pii">AMSU-D-23-01218</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Batchelor TT. Primary central nervous system lymphoma: a curable disease. Hematol Oncol 2019;37(S1):15&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">31187523</ArticleId></ArticleIdList></Reference><Reference><Citation>Agha RA, Franchi T, Sohrabi C, et al. . and SCARE Group. The SCARE 2020 guideline: updating consensus Surgical CAse REport (SCARE) guidelines. Int J Surg 2020;84:226&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">33181358</ArticleId></ArticleIdList></Reference><Reference><Citation>Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer 2017;123:4314&#x2013;4324.</Citation><ArticleIdList><ArticleId IdType="pubmed">28950405</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang M, Cleveland J, Rubenstein JL. On point in primary CNS lymphoma. Hematol Oncol 2020;38:640&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8815361</ArticleId><ArticleId IdType="pubmed">32510610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C-C, Carnevale J, Rubenstein JL. Progress in central nervous system lymphomas. Br J Haematol 2014;166:311&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107064</ArticleId><ArticleId IdType="pubmed">24837460</ArticleId></ArticleIdList></Reference><Reference><Citation>Barajas RF, Politi LS, Anzalone N, et al. . Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 2021;23:1056&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248856</ArticleId><ArticleId IdType="pubmed">33560416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragu&#x17e; M, Mudrov&#x10d;i&#x107; Y, Dlaka D, et al. . Primary dural lymphoma mimicking meningioma: a clinical and surgical case report. J Surg Case Rep 2018;2018:rjy189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077807</ArticleId><ArticleId IdType="pubmed">30093991</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini J, Kumar Gupta P, Awasthi A, et al. . Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI. Clin Radiol 2018;73:986.e7&#x2013;986.e15.</Citation><ArticleIdList><ArticleId IdType="pubmed">30197047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambady P, Hu LS, Politi LS, et al. . Primary central nervous system lymphoma: advances in MRI and PET imaging. Ann Lymphoma 2021;5:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9387672</ArticleId><ArticleId IdType="pubmed">35994050</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein JL, Hsi ED, Johnson JL, et al. . Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013;31:3061&#x2013;3068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753699</ArticleId><ArticleId IdType="pubmed">23569323</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka R, Homma J, Sano M, et al. . Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study. Leuk Lymphoma 2007;48:1429&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pubmed">17613777</ArticleId></ArticleIdList></Reference><Reference><Citation>Doorduijn JK, van Imhoff GW, van der Holt B, et al. . Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematol Oncol 2017;35:497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">27530779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Sun P, Cui J, et al. . High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: a retrospective study from China. Cancer Med 2019;8:1359&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6488123</ArticleId><ArticleId IdType="pubmed">30821418</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass J, Won M, Schultz CJ, et al. . Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. J Clin Oncol 2016;34:1620&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872318</ArticleId><ArticleId IdType="pubmed">27022122</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program 2017;2017:565&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142584</ArticleId><ArticleId IdType="pubmed">29222306</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia CE, Schaff LR, Grommes C. Central nervous system lymphoma: approach to diagnosis and treatment. Cancer J 2020;26:241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">32496457</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang-Xuan K, Bessell E, Bromberg J, et al. . Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015;16:e322&#x2013;e332.</Citation><ArticleIdList><ArticleId IdType="pubmed">26149884</ArticleId></ArticleIdList></Reference><Reference><Citation>Calimeri T, Steffanoni S, Gagliardi F, et al. . How we treat primary central nervous system lymphoma. ESMO Open 2021;6:100213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287145</ArticleId><ArticleId IdType="pubmed">34271311</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>